Prescription Drugs

Today’s U.S. patent system does not always live up to its idealistic portrayal

Reducing prescription drug prices has long been a goal of Democrats in Congress and the White House. Has that changed?

A proposed bipartisan bill aims to curb this practice

Under the new guidance, there is genuine potential to curtail outlandish drug prices. However, the new guidance carries some real risk for Medicare beneficiaries

Europe designates all biosimilars as interchangeable with original biologics. It’s time for the United States to do the same

The most consequential part of the decision memo clarified Medicaid's responsibilities in covering the drug

The FDA's standards for accelerated approval are only effective if they are enforced